Greg M. Arndt

High Street
Randwick, NSW 2052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Invasion-Block and S-MARVEL: A high-content screening and image analysis platform identifies ATM kinase as a modulator of melanoma invasion and metastasis.

Invasion-Block and S-MARVEL: A high-content screening and image analysis platform identifies ATM kinase as a modulator of melanoma invasion and metastasis.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: November 14, 2023

FDA-approved disulfiram as a novel treatment for aggressive leukemia.

FDA-approved disulfiram as a novel treatment for aggressive leukemia.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: May 26, 2023

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms.

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms.

Journal: EBioMedicine

Published: December 21, 2022

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.

Journal: Cancer research

Published: November 28, 2022

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.

Journal: Blood

Published: October 03, 2022

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.

Journal: Frontiers in oncology

Published: January 27, 2022

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Journal: Frontiers in oncology

Published: September 20, 2021

βIII-tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c-Met positive non-small cell lung cancer cells.

βIII-tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c-Met positive non-small cell lung cancer cells.

Journal: Cancer medicine

Published: August 18, 2021

Synthesis and Characterisation of Novel Tricyclic and Tetracyclic Furoindoles: Biological Evaluation as SAHA Enhancer against Neuroblastoma and Breast Cancer Cells.

Synthesis and Characterisation of Novel Tricyclic and Tetracyclic Furoindoles: Biological Evaluation as SAHA Enhancer against Neuroblastoma and Breast Cancer Cells.

Journal: Molecules (Basel, Switzerland)

Published: August 10, 2021

In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.

In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.

Journal: EMBO molecular medicine

Published: May 28, 2021

The important role of routine cytopathology in pediatric precision oncology.

The important role of routine cytopathology in pediatric precision oncology.

Journal: Cancer cytopathology

Published: March 15, 2021

Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.

Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.

Journal: Cancers

Published: February 15, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026